Satellite Banner
Molecular & Clinical Diagnostics
Scientific Community
Become a Member | Sign in
Home>News>This Article

Financing Raised for Novel Molecular Diagnostic for MS

Published: Wednesday, December 19, 2012
Last Updated: Wednesday, December 19, 2012
Bookmark and Share
Molecular diagnostics company DioGenix, Inc. announced it raised $1.5 million in Series B financing.

Existing investors including life sciences fund Nerveda LLC participated in the round to support a prospective, multi-site clinical trial to validate MS™, DioGenix’ proprietary next-generation sequencing test for the early identification and diagnosis of multiple sclerosis (MS).

In a recently completed study, MS outperformed the specificity of the current standard of care for cerebral spinal fluid (CSF) analysis in patients suspected of having MS by almost two to one with no loss of sensitivity. The results of the clinical study are consistent with two prior DioGenix studies, warranting further validation of the deep-sequencing approach in a large, 150-subject validation trial that is currently underway.

“DioGenix continues to execute its strategy to develop MS as a diagnostic to accurately identify patients in the early stages of multiple sclerosis. The team has a solid track record developing and commercializing products that elevate the standards of diagnosing disease, and I have confidence they can do it again,” said Cam Gallagher, Chairman of DioGenix and President of Nerveda LLC, a private life science fund dedicated to advancing novel therapeutic and diagnostic technologies for neurodegenerative diseases.

“We’ve made excellent progress executing our plan to give physicians superior tools and greater confidence when they diagnose multiple sclerosis. We expect MS to provide a vast improvement in the information available to neurologists as they evaluate patients presenting with variable symptoms of neurodegenerative disease,” said Larry Tiffany, President and Chief Executive Officer, DioGenix, Inc.

Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,500+ scientific posters on ePosters
  • More than 5,200+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Scientific News
Point of Care Diagnostics - A Cautious Revolution
Advances in molecular biology, coupled with the miniaturization and improved sensitivity of assays and devices in general, have enabled a new wave of point-of-care (POC) or “bedside” diagnostics.
Smartphone Laboratory Detects Cancer
Researchers develop low-cost, portable laboratory on a smartphonecapable of analysing multiple samples simultaneously.
Nanomedicine for Breast Cancer Treatment
Using nanoparticles measuring only billionths of a meter in size, doctors are able to deliver drug molecules directly to the affected tissue.
Clamping Down on Biomolecules
Physicists have developed a novel nanotool that provides a means of characterizing the mechanical properties of biomolecules.
MRIs for Fetal Health
Algorithm could help analyze fetal scans to determine whether interventions are warranted.
Illumina Contributes to ClinVar Database
The contribution includes variants of all classifications, from pathogenic to benign, identified during interpretation of whole genome sequences generated in the CLIA-certified, CAP-accredited Illumina Clinical Services Laboratory.
Signaling Pathway Could Be Key to Improved Osteoporosis Treatment
Inhibition of SIK2 enzyme both stimulates bone formation and reduces bone breakdown in animal model.
Supercomputers Could Improve Cancer Diagnostics
Researchers push the boundaries of cancer research through high-performance computing to map the human immunone.
Transgenomic, Precipio Diagnostics Merger
Merger will creates a robust diagnostic platform focused on improving accuracy of cancer diagnoses.
Inflammation Test May Predict Cardiovascular Disease
An assessment combining measures of immune-cell responsiveness predicted cardiovascular problems in individuals who likely would have slipped under the radar.
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,200+ scientific videos